Bravo Taishi Ł Kimura and Jesse Erasmus, this is great work with help from many others on the team HDT Bio doi.org/10.1016/j.ymth…

The results of a recent study published in Molecular Therapy suggest that in vivo administration of repRNA by LION™, HDT Bio’s technology for delivering #RNA #vaccines, is safer than other formulation technologies. Learn more: prnewswire.com/news-releases/…

Our CSO, Peter Berglund, is presenting today at the #mRNA #Cancer #Vaccine Summit. Check out his talk on improving the toxicity of mRNA cancer vaccines if you’re there! Learn more about HDT Bio’s vaccine platform: hdt.bio/technology

BARDA is partnering w/ HDT Bio under #ProjectNextGen’s Enablers program to support proof-of-concept studies for on-demand manufacturing & release processes that use HDT Bio’s LION formulation for mRNA vaccine production. Learn more about Project NextGen: ow.ly/FvSh50Q4QM1

Enabling self-amplifying RNA vaccines with ⁦HDT Bio⁩ ‘s LION formulation. More on this in my interview with ⁦Vaccine Insights⁩ insights.bio/vaccine-insigh…

Our Co-founder and COO Chris Pirie, Ph.D., (Christopher Pirie) and five other biopharma executives spoke with BioWorld about financial struggles the biopharma space faced this past year, and why we’re optimistic for a better 2024. bioworld.com/media/podcasts…

Biology is complex. But every day we get a little bit closer to understanding the nature of all its glory. Ang Cui, Ph.D. and her colleagues have brought us closer. If you're developing vaccines and haven't read this paper, you're doing yourself a disservice. HDT Bio

Today, we announced the receipt of a $749,000 EZBAA contract through a partnership with BARDA under #ProjectNextGen’s Enabler’s program. The contract will support studies providing proof-of-concept data for our #RNA #vaccine LION™ platform and more. prnewswire.com/news-releases/…

This week on #BioTechNation, Dr. Chris Pirie, Co-Founder & COO of HDT Bio joins us to talk about their groundbreaking approaches to cancer prevention through vaccines. Listen Now: ow.ly/wTga50R6Ve2 #CancerPrevention #Vaccines

VC Fund size to DPI plot - 168 funds covered & Vintage year 2014-2016 1. Only ~20% are in the carry 2. >$2B barely returned deployed capital back to LPs (not including fees/hurdle) 3. Median fund size of $200M returned >1.5x DPI Will post other thematic observations later

When starting a company myself or advising venture teams, I'm often faced with the question "How much should we raise?" While the answer is usually some variation of "It depends", I find that too often we don't consider the cultural and behavioral consequences of the choice.

HDT Bio recently spoke to Moira Gunn of Moira Gunn to discuss the company’s progress in #RNAvaccine development and walk her through how our revolutionary repRNA/ LION™ platform works. Listen here: bit.ly/44k4g3h

Today I had the pleasure of being invited by Suzie Pun to lecture in her UW Bioengineering BIOEN 491 that I took as an undergraduate more than a decade ago. It was great reflect on the accomplishments of years gone by and hopefully provide a bit of perspective for those bright young minds.

Listening to HeatherHartnett talk about founding team composition with aligned values and skill cross-section is really resonating. Clarity of purpose/accountability from the start is super important.

For everyone screaming that pharma is taking advantage of patients (fwiw it's generally the system not the companies), please take a look at this table at start focusing on how the banks and oil companies are taking advantage of main street. pages.stern.nyu.edu/~adamodar/New_…

Awesome collaboration with the McGuire Lab now published! Use of HDT Bio’s LION/repRNA platform to prevent #EBV infection of humanized mice. nature.com/articles/s4154…

Excited to be attending the #BBGGreenFestival hosted by Bloomberg Live during #PNWCW2024 and participating in the Climate Tech Challenge from Leaner Startups and a variety of other affiliated networking events. Should be a busy and fun week.

(NEW EPISODE) He Raised $100 Million For A Company And Merged With Inscripta, And Is Now Converting Waste Into Valuable Products To Decarbonize The Chemicals Industry Christopher Pirie alejandrocremades.com/he-raised-100-… #entrepreneur #business #success